Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

The findings, which confirm the biosimilar’s efficacy and safety profile compared to Stelara, are being presented at the 2025 ...

Bengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced ...

This Phase 3 study reaffirms the quality and therapeutic equivalence of YESINTEK compared to reference product, Stelara. The study demonstrated equivalent efficacy, safety, immunogenicity ...

Simlandi and adalimumab-adaz have been with on formulary, along with Humira, beginning Jan. 1, 2025, Arpit Patel, Pharm.D., ...

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara (Ustekinumab), marking a significant milestone for ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...